Newsbenzinga
Vanda Eyes First FDA-Approved Delayed Sleep-Wake Disorder Drug
· Published
Article summary
Vanda's Phase 3 trial of HETLIOZ for DSWPD met its primary endpoint, advancing sleep onset by 42.5 minutes. sNDA submission planned.
An excerpt from the original article.
Comments —
Loading comments…